
Neurology
2 Mar 2025
Ketogenic Diet Modulates Immune Function in MS: ACTRIMS 2025
At the ACTRIMS Forum 2025 in West Palm Beach, Florida, researchers unveiled compelling findings on the effects of a 6-month modified Atkins diet (MAD), a less restrictive form of the ketogenic diet, on patients with relapsing multiple sclerosis (MS).

Neurology
2 Mar 2025
Tolebrutinib Targets Chronic Lesions in MS Treatment: ACTRIMS 2025
A new analysis of Phase III clinical trial data presented at the ACTRIMS Forum 2025 in West Palm Beach, Florida, suggests that tolebrutinib, a Bruton’s tyrosine kinase inhibitor (BTKi), may be effective in multiple sclerosis (MS) with chronic active lesions.
Latest Articles
Interactive Content
Latest Journals
All JournalsCongress Reviews
All Congress ReviewsLatest Infographics
All InfographicsLatest Podcasts
All Podcasts